FDA Grants Lirafugratinib Priority Review in FGFR2-Altered CholangiocarcinomaByErin DoranMarch 30th 2026
FDA Endorses Phase 3 Design for Oncolytic Virus in Metastatic PDACByErin DoranPublished: March 26th 2026 | Updated: March 25th 2026